KUALA LUMPUR, 07 December 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601) today announced that its wholly owned subsidiary HWGB Biotech Sdn Bhd (HWGB Biotech) had submitted a letter to MOH to seek MOH’s support in expediting the approval for HWGB Biotech to carry out a research study titled “OPV As A Preventive Protection Against The SARS-Cov-2 Virus” and to explore potential collaboration with MOH in the research.
This is no doubt a positive step for HWGB Biotech in its efforts to expedite the entry of EBI’s Covid-19 vaccine for private sector use in Malaysia in the event EBI’s Covid-19 vaccine is proven effective for the preventive protection against Covid-19. Further, HWGB Biotech had also on today appointed Prima Nexus Sdn Bhd (“Prima Nexus”) as the research resource management consulting firm for the research study. Prima Nexus works together with institutions and organizations to provide a comprehensive package of research services to both clinicians and researchers.
HWGB Biotech’s Investigator for the research study, Dato Dr. Lai Kwong Choy, said: “Our aim is to provide a solution that is relatively affordable, easily available and easy to be administered to the Malaysian public in hope to give the Malaysian Government a hand in Malaysia’s recovery from what has been a tumultuous year and ensuring the Rakyat’s well-being.”
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in health supplement, biotechnology and health technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wires and cables; and travel agent and tour related services.
HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the ddistribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.
Please refer to the US Food and Drug Administration website for more information on EBI’s Phase IV clinical study : https://www.clinicaltrials.gov/ct2/show/NCT04639375
For more information on about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, Facebook, LinkedIn and Telegram to view the latest updates about our company ventures in the healthcare industry.
Dato’ Dr.Lai Kwong Choy, Chief Medical Consultant of HWGB Biotech
A medical doctor with practices at various clinics with over 30 year of relevant experience in the medical field. He is also the former board member of Malaysia Health Promotion Board under the MOH and has served as a local counsellor at the Kajang Municipal Council.
Prima Nexus Sdn Bhd was incorporated in Malaysia under the Act on 23 July 2013, is a homegrown multiracial and dedicated research resource management provider in diverse research, clinical, therapeutic and diagnostic areas.